Role of Tocilizumab in COVID-19 Pneumonia patients
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/08/027246
- Lead Sponsor
- GCS Medical College Hospital and Research Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
RT-PCR COVID-19 Test Positive patients will be included
Moderate to Severe COVID Pneumonia patients will be included
Exclusion Criteria
Patients with Active Tuberculosis, Past history of Tuberculosis, Other active suspected Viral/Fungal infection, Platelet count <50,000/ml and Absolute Pneutrophil Count <1000/ml will be excluded
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Role of Tocilizumab in COVID-19 PneumoniaTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method To know the efficacy of Tocilizumab in COVID-19 Pneumonia patientsTimepoint: 3 months